To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of NASH.

However, no therapeutic medications for NASH have yet been launched.

One of the reasons is the lack of animal models that can completely reproduce the pathology of NASH as seen in humans due to the complex pathological progression of the disease.

Considering the difficulty to establish an animal model that corresponds to the complexity of the pathology, it is necessary to use multiple animal models and evaluate the efficacy against the disease from a multifaceted perspective.

Our proprietary NASH-HCC model (STAM™ model) is characterized by a similar disease progression to human NASH (fatty liver → NASH → liver fibrosis → HCC) but does not cause liver cirrhosis. Therefore, we believe that we can provide total support for the development of NASH therapy at the preclinical stage through implementing and complementing this model with the CCl₄-induced liver fibrosis model (CCl₄ model) which is a model of liver cirrhosis.

Please also find below a comparison table of the STAM™ and CCl₄ models.

If you are interested in a model or combination of models for evaluating your compounds, please contact us.